XR 5082
Latest Information Update: 01 Aug 2002
Price :
$50 *
At a glance
- Originator Xenova Group
- Class Antithrombotics; Plasminogen activator enzymes
- Mechanism of Action Plasminogen activator inhibitor-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis; Unstable angina pectoris
Most Recent Events
- 01 Aug 2002 Discontinued - Preclinical for Thrombosis in United Kingdom (unspecified route)
- 01 Aug 2002 Discontinued - Preclinical for Unstable angina pectoris in United Kingdom (unspecified route)
- 03 Sep 1998 No-Development-Reported for Thrombosis in United Kingdom (Unknown route)